Pmv Pharmaceuticals, Inc. (PMVP)
NASDAQ:PMVP
Want to see PMVP full AI Analyst Report?
Top Page
PMV Pharmaceuticals
(NASDAQ:PMVP)
Select Model
Select Model
Rating:42Neutral
Price Target:
$1.00
▼(-10.71% Downside)
Action:Reiterated
Date:05/14/26
The score is driven primarily by weak financial performance (pre-revenue, large ongoing losses and heavy cash burn implying continued funding dependence). Technicals also weigh on the score with the stock trading below major moving averages and weak momentum signals. Valuation provides limited support because the P/E is negative and no dividend yield is available.
Positive Factors
p53‑targeted pipeline
A concentrated scientific focus on restoring/enhancing p53 gives PMV a clear differentiation in precision oncology. Durable advantage: a specific mechanism that can address multiple tumor types with p53 alterations, concentrating R&D expertise and enabling targeted clinical paths and partnership value if clinical signals emerge.
Negative Factors
High and persistent cash burn
Sustained negative operating and free cash flow at this magnitude creates ongoing financing dependence and consistent dilution risk. Over the next several months, program progression will require material capital infusions; funding timing and terms could force tradeoffs across the pipeline or slow development cadence.
Read all positive and negative factors
Positive Factors
Negative Factors
p53‑targeted pipeline
A concentrated scientific focus on restoring/enhancing p53 gives PMV a clear differentiation in precision oncology. Durable advantage: a specific mechanism that can address multiple tumor types with p53 alterations, concentrating R&D expertise and enabling targeted clinical paths and partnership value if clinical signals emerge.
Read all positive factors
PMV Pharmaceuticals (PMVP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$64.00M
Dividend YieldN/A
Average Volume (3M)374.17K
Price to Earnings (P/E)―
Beta (1Y)0.46
Revenue GrowthN/A
EPS Growth-26.14%
CountryUS
Employees47
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.49
Shares Outstanding53,331,764
10 Day Avg. Volume330,032
30 Day Avg. Volume374,171
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)0.63
Price to Sales (P/S)0.00
P/FCF Ratio-0.89
Enterprise Value/Market Cap0.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-381.23
Enterprise Value/Ebitda-0.31
Forecast
1Y Price Target
$4.50Price Target Upside301.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.57
Revenue Forecast (FY)N/A
PMV Pharmaceuticals Business Overview & Revenue Model
Company Description
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that co...
How the Company Makes Money
PMV Pharmaceuticals is a clinical-stage biopharmaceutical company and, as such, it typically does not generate recurring product sales revenue because it does not have broadly marketed, commercial-stage drugs. Its potential and/or historical sourc...
PMV Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
58
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -66.00K | 0.00 | -1.14M | -1.26M | -650.00K | -1.28M |
| EBITDA | -81.86M | -86.07M | -73.67M | -67.70M | -72.68M | -56.54M |
| Net Income | -78.34M | -77.74M | -58.71M | -68.96M | -73.32M | -57.85M |
Balance Sheet | ||||||
| Total Assets | 96.56M | 116.56M | 191.29M | 252.15M | 270.31M | 331.57M |
| Cash, Cash Equivalents and Short-Term Investments | 93.55M | 112.94M | 169.45M | 203.06M | 241.05M | 297.16M |
| Total Debt | 293.00K | 838.00K | 1.19M | 13.29M | 13.98M | 11.19M |
| Total Liabilities | 8.60M | 11.85M | 15.21M | 26.46M | 24.28M | 23.01M |
| Stockholders Equity | 87.97M | 104.71M | 176.08M | 225.69M | 246.03M | 308.56M |
Cash Flow | ||||||
| Free Cash Flow | -75.02M | -73.61M | -51.94M | -56.62M | -71.74M | -47.92M |
| Operating Cash Flow | -74.99M | -73.58M | -51.28M | -55.66M | -63.76M | -46.57M |
| Investing Cash Flow | 62.28M | 70.17M | 53.35M | -50.55M | -1.37M | -143.58M |
| Financing Cash Flow | 495.00K | 505.00K | 313.00K | 35.58M | 958.00K | 2.02M |
PMV Pharmaceuticals Technical Analysis
Negative
1.12
Price Trends
1.35
Negative
1.31
Negative
1.33
Negative
Market Momentum
-0.05
Positive
35.99
Neutral
5.56
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PMVP, the sentiment is Negative. The current price of 1.12 is below the 20-day moving average (MA) of 1.32, below the 50-day MA of 1.35, and below the 200-day MA of 1.33, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 35.99 is Neutral, neither overbought nor oversold. The STOCH value of 5.56 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PMVP.
PMV Pharmaceuticals Risk Analysis
PMV Pharmaceuticals disclosed 77 risk factors in its most recent earnings report. PMV Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
PMV Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $83.18M | -3.88 | -201.43% | ― | ― | 33.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $312.21M | -4.16 | -118.24% | ― | 138.86% | 42.14% | |
50 Neutral | $406.52M | -5.46 | -94.90% | ― | -71.26% | -300.04% | |
46 Neutral | $36.66M | -3.81 | -70.28% | ― | -100.00% | -170.04% | |
42 Neutral | $64.00M | -0.82 | -68.98% | ― | ― | -26.14% |
* Healthcare Sector Average
PMVP
PMV Pharmaceuticals
1.20
0.32
36.36%
XFOR
X4 Pharmaceuticals
4.31
0.50
13.12%
ABVC
ABVC BioPharma
1.41
-0.13
-8.44%
PRLD
Prelude Therapeutics
3.92
3.01
330.77%
GANX
Gain Therapeutics
1.95
0.02
1.04%
IMMX
Immix Biopharma
9.00
6.40
246.15%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.